vs
CLOVER HEALTH INVESTMENTS, CORP.（CLOV）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
Royalty Pharma plc的季度营收约是CLOVER HEALTH INVESTMENTS, CORP.的1.3倍（$622.0M vs $487.7M），Royalty Pharma plc净利率更高（34.4% vs -10.1%，领先44.6%），CLOVER HEALTH INVESTMENTS, CORP.同比增速更快（44.7% vs 4.8%），过去两年CLOVER HEALTH INVESTMENTS, CORP.的营收复合增速更高（18.6% vs 4.6%）
克利弗健康投资公司是2014年成立的美国医疗保健企业，主营联邦医疗保险优势计划保险产品，是与美国政府直接签约合作的机构。目前公司为美国11个州的联邦医疗保险参保人提供健康管理服务，并已于2021年1月8日公开上市。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
CLOV vs RPRX — 直观对比
营收规模更大
RPRX
是对方的1.3倍
$487.7M
营收增速更快
CLOV
高出40.0%
4.8%
净利率更高
RPRX
高出44.6%
-10.1%
两年增速更快
CLOV
近两年复合增速
4.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $487.7M | $622.0M |
| 净利润 | $-49.3M | $214.2M |
| 毛利率 | — | — |
| 营业利润率 | -10.1% | 62.4% |
| 净利率 | -10.1% | 34.4% |
| 营收同比 | 44.7% | 4.8% |
| 净利润同比 | -123.2% | 2.9% |
| 每股收益（稀释后） | — | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CLOVRPRX
| Q4 25 | $487.7M | $622.0M | ||
| Q3 25 | $496.6M | $609.3M | ||
| Q2 25 | $477.6M | $578.7M | ||
| Q1 25 | $462.3M | $568.2M | ||
| Q4 24 | $337.0M | $593.6M | ||
| Q3 24 | $331.0M | $564.7M | ||
| Q2 24 | $356.3M | $537.3M | ||
| Q1 24 | $346.9M | $568.0M |
净利润CLOVRPRX
| Q4 25 | $-49.3M | $214.2M | ||
| Q3 25 | $-24.4M | $288.2M | ||
| Q2 25 | $-10.6M | $30.2M | ||
| Q1 25 | $-1.3M | $238.3M | ||
| Q4 24 | $-22.1M | $208.2M | ||
| Q3 24 | $-9.2M | $544.0M | ||
| Q2 24 | $7.4M | $102.0M | ||
| Q1 24 | $-19.2M | $4.8M |
毛利率CLOVRPRX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 24.5% | — | ||
| Q2 24 | 30.3% | — | ||
| Q1 24 | 23.6% | — |
营业利润率CLOVRPRX
| Q4 25 | -10.1% | 62.4% | ||
| Q3 25 | -4.9% | 70.1% | ||
| Q2 25 | -2.2% | 36.3% | ||
| Q1 25 | -0.3% | 94.0% | ||
| Q4 24 | -6.4% | 60.9% | ||
| Q3 24 | -2.7% | — | ||
| Q2 24 | 2.0% | 50.2% | ||
| Q1 24 | -6.5% | -13.0% |
净利率CLOVRPRX
| Q4 25 | -10.1% | 34.4% | ||
| Q3 25 | -4.9% | 47.3% | ||
| Q2 25 | -2.2% | 5.2% | ||
| Q1 25 | -0.3% | 41.9% | ||
| Q4 24 | -6.6% | 35.1% | ||
| Q3 24 | -2.8% | 96.3% | ||
| Q2 24 | 2.1% | 19.0% | ||
| Q1 24 | -5.5% | 0.8% |
每股收益（稀释后）CLOVRPRX
| Q4 25 | — | $0.49 | ||
| Q3 25 | — | $0.67 | ||
| Q2 25 | — | $0.07 | ||
| Q1 25 | — | $0.55 | ||
| Q4 24 | — | $0.46 | ||
| Q3 24 | — | $1.21 | ||
| Q2 24 | — | $0.23 | ||
| Q1 24 | — | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $78.3M | $618.7M |
| 总债务越低越好 | — | $9.0B |
| 股东权益账面价值 | $308.7M | $9.7B |
| 总资产 | $541.0M | $19.6B |
| 负债/权益比越低杠杆越低 | — | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资CLOVRPRX
| Q4 25 | $78.3M | $618.7M | ||
| Q3 25 | — | $938.9M | ||
| Q2 25 | — | $631.9M | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | $194.5M | $929.0M | ||
| Q3 24 | $288.0M | $950.1M | ||
| Q2 24 | $254.8M | $1.8B | ||
| Q1 24 | $208.3M | $843.0M |
总债务CLOVRPRX
| Q4 25 | — | $9.0B | ||
| Q3 25 | — | $8.9B | ||
| Q2 25 | — | $8.0B | ||
| Q1 25 | — | $7.6B | ||
| Q4 24 | — | $7.6B | ||
| Q3 24 | — | $7.6B | ||
| Q2 24 | — | $7.6B | ||
| Q1 24 | — | $6.1B |
股东权益CLOVRPRX
| Q4 25 | $308.7M | $9.7B | ||
| Q3 25 | $340.9M | $9.6B | ||
| Q2 25 | $344.2M | $9.5B | ||
| Q1 25 | $336.1M | $9.8B | ||
| Q4 24 | $341.1M | $10.3B | ||
| Q3 24 | $342.2M | $10.3B | ||
| Q2 24 | $324.9M | $9.8B | ||
| Q1 24 | $292.5M | $9.9B |
总资产CLOVRPRX
| Q4 25 | $541.0M | $19.6B | ||
| Q3 25 | $559.7M | $19.3B | ||
| Q2 25 | $575.0M | $18.3B | ||
| Q1 25 | $583.7M | $17.6B | ||
| Q4 24 | $580.7M | $18.2B | ||
| Q3 24 | $653.0M | $18.0B | ||
| Q2 24 | $674.2M | $17.7B | ||
| Q1 24 | $671.8M | $16.1B |
负债/权益比CLOVRPRX
| Q4 25 | — | 0.92× | ||
| Q3 25 | — | 0.93× | ||
| Q2 25 | — | 0.84× | ||
| Q1 25 | — | 0.78× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | — | 0.74× | ||
| Q2 24 | — | 0.78× | ||
| Q1 24 | — | 0.62× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-66.9M | $827.1M |
| 自由现金流经营现金流 - 资本支出 | $-69.0M | — |
| 自由现金流率自由现金流/营收 | -14.1% | — |
| 资本支出强度资本支出/营收 | 0.4% | — |
| 现金转化率经营现金流/净利润 | — | 3.86× |
| 过去12个月自由现金流最近4个季度 | $-69.2M | — |
8季度趋势，按日历期对齐
经营现金流CLOVRPRX
| Q4 25 | $-66.9M | $827.1M | ||
| Q3 25 | $12.1M | $702.6M | ||
| Q2 25 | $5.4M | $364.0M | ||
| Q1 25 | $-16.3M | $596.1M | ||
| Q4 24 | $34.8M | $742.5M | ||
| Q3 24 | $50.0M | $703.6M | ||
| Q2 24 | $44.8M | $658.2M | ||
| Q1 24 | $25.9M | $664.6M |
自由现金流CLOVRPRX
| Q4 25 | $-69.0M | — | ||
| Q3 25 | $11.4M | — | ||
| Q2 25 | $4.8M | — | ||
| Q1 25 | $-16.5M | — | ||
| Q4 24 | $33.3M | — | ||
| Q3 24 | $49.6M | — | ||
| Q2 24 | $44.4M | — | ||
| Q1 24 | $25.5M | — |
自由现金流率CLOVRPRX
| Q4 25 | -14.1% | — | ||
| Q3 25 | 2.3% | — | ||
| Q2 25 | 1.0% | — | ||
| Q1 25 | -3.6% | — | ||
| Q4 24 | 9.9% | — | ||
| Q3 24 | 15.0% | — | ||
| Q2 24 | 12.5% | — | ||
| Q1 24 | 7.3% | — |
资本支出强度CLOVRPRX
| Q4 25 | 0.4% | — | ||
| Q3 25 | 0.1% | — | ||
| Q2 25 | 0.1% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.5% | — | ||
| Q3 24 | 0.1% | — | ||
| Q2 24 | 0.1% | — | ||
| Q1 24 | 0.1% | — |
现金转化率CLOVRPRX
| Q4 25 | — | 3.86× | ||
| Q3 25 | — | 2.44× | ||
| Q2 25 | — | 12.06× | ||
| Q1 25 | — | 2.50× | ||
| Q4 24 | — | 3.57× | ||
| Q3 24 | — | 1.29× | ||
| Q2 24 | 6.04× | 6.45× | ||
| Q1 24 | — | 139.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CLOV
暂无分部数据
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
